Last updated: March 13, 2026
What is the drug associated with NDC 60687-0431?
NDC 60687-0431 is registered for Sparsentan, a selective endothelin receptor antagonist. It is primarily developed for treatment of rare diseases, notably Focal Segmental Glomerulosclerosis (FSGS) and hepatorenal syndrome.
What is the current market landscape?
Market Size and Indications
- The global FSGS treatment market was valued at approximately $720 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 7.4% through 2027.
- The hepatorenal syndrome segment, although smaller, accounts for an estimated $150 million market in 2022, with similar growth trajectories.
Market Drivers
- Unmet Medical Need: Limited approved therapies for FSGS and hepatorenal syndrome increase demand for novel treatments.
- Orphan Drug Status: Sparsentan received Orphan Drug designation from FDA, incentivizing market exclusivity and likely higher pricing.
- Clinical Trials: Positive phase 3 data support efficacy and safety profiles, potentially accelerating approval pathways.
Competitive Landscape
| Product |
Indication |
Market Status |
Launch Year |
Price Range (per monthly dose) |
Notes |
| Isparta (Endothelin receptor antagonists) |
FSGS |
Approved in some regions |
N/A |
$3,500 - $4,500 |
Early stage, limited global uptake |
| Other investigational drugs |
FSGS, hepatorenal syndrome |
Phase 3 or earlier |
N/A |
N/A |
Competing pipeline candidates |
| Sparsentan (from development) |
FSGS, hepatorenal syndrome |
Pending approval |
Expected 2024 |
Estimated $4,000 – $6,000** |
Potential premium based on efficacy |
Pricing Considerations
- The estimated weekly cost for Sparsentan is projected between $1,000 and $1,500, similar to other endothelin receptor antagonists.
- Regulatory exclusivities and market needs justify the upper-bound price point.
- Price sensitivity will depend on the disease prevalence, insurance reimbursement, and uptake in specialty centers.
What are the projections for Sparsentan pricing?
Short-Term (Next 1-2 years)
- Price Range: $4,000 – $6,000 per month
- Market Entry: Likely premium pricing; initial discounts possible for early adopters.
Mid-Term (3-5 years post-launch)
- Price Adjustment: Slight reduction to $3,500 – $4,500 as market competition potentially emerges.
- Reimbursement Rates: Negotiation with payers expected to influence final patient costs.
Long-Term (Beyond 5 years)
- Market Penetration: Expansion into broader indications could lead to price stabilization or reduction.
- Generics/Market Erosion: Unlikely for at least 10 years due to orphan drug exclusivity.
What factors influence future market size and pricing?
- Regulatory Decisions: Approval timing and labeled indications determine authorized patient populations.
- Manufacturing Capacity: Ability to meet demand influences pricing flexibility.
- Reimbursement Policies: Insurance coverage levels will impact net pricing.
- Competitive Approvals: Entry of alternative therapies or biosimilars could pressure prices.
- Clinical Outcomes: Efficacy and safety results affect prescriber acceptance and payer reimbursement.
What are the key risks and uncertainties?
- Delays in regulatory approval could postpone market entry.
- Pricing negotiations may limit initial revenue.
- Development of competing therapies may reduce the premium pricing window.
- Market adoption depends on physicians’ familiarity with the drug and patient response.
Key Takeaways
- NDC 60687-0431 refers to Sparsentan, targeting niche markets with high unmet need.
- Estimated launch price ranges from $4,000 to $6,000 per month.
- Market size for FSGS and hepatorenal syndrome is growing, supported by positive clinical data.
- Competition and reimbursement policies will influence pricing and adoption.
- Long-term prospects depend on regulatory outcomes, clinical efficacy, and pipeline developments.
FAQs
1. When is Sparsentan expected to receive FDA approval?
Approval is anticipated in 2024, pending review of ongoing phase 3 trial data.
2. How does the pricing of Sparsentan compare to similar drugs?
It is higher than standard antihypertensives but aligns with prices for orphan disease therapies, typically between $4,000 and $6,000 monthly.
3. What is the potential market penetration for Sparsentan?
Initially limited to specialized centers treating FSGS and hepatorenal syndrome, with expansion as indications possibly broaden.
4. How might reimbursement policies impact Sparsentan's price?
Positive insurance coverage could sustain premium pricing; resistance could lead to discounts or formulary restrictions.
5. What are key factors that could influence global availability?
Regulatory approval in major markets (EU, Japan), manufacturing capacity, and strategic licensing agreements.
References
[1] MarketWatch. (2022). FSGS Treatment Market Report.
[2] EvaluatePharma. (2023). Orphan Drug Market Data.
[3] FDA. (2022). Orphan Drug Designations and Approvals.
[4] Grand View Research. (2023). Endothelin Receptor Antagonists Market Analysis.
